Clinical Trials Browser

Completed × pembrolizumab × Plasma cell × Clear all

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03267888 2024-09-04

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

25 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT03848845 2024-04-09

DREAMM 4

Phase 1/2 Completed

41 enrolled 57 charts

Plasma cell

Multiple Myeloma

NCT03506360 2024-01-09

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 2 Completed

13 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT02636010 2020-04-29

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Phase 2 Completed

20 enrolled

Plasma cell

Multiple Myeloma

NCT02331368 2018-07-27

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Phase 2 Completed

32 enrolled 8 charts

Plasma cell

Multiple Myeloma

Clinical Trials

KEYNOTE145

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

DREAMM 4

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

MK-3475-013

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma